Literature DB >> 8874504

Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.

K Hiramatsu1, M Tadano, R Men, C J Lai.   

Abstract

The antigenic site of dengue type 2 virus (DEN2)-neutralizing monoclonal antibody (mab) 3H5 was investigated by mutational analysis. Sequence comparisons indicated that much of the 12-amino-acid sequence extending from position 386 to 397 of the DEN2 envelope glycoprotein (E) previously thought to represent the DEN2-specific mab 3H5 binding site was also present in some dengue type 1, 3, or 4 virus strains. However, the region occupied by the Glu-Pro-Gly sequence at upstream positions 383 to 385 was completely conserved among DEN2 strains, but divergent in other serotype viruses, suggesting that this sequence might be part of the antigenic site of mab 3H5. We investigated this possibility by employing the previously constructed chimeric DEN2(PreM-E)/DEN4 cDNA clone to produce viable mutants bearing DEN2 PreM and E sequences that could be analyzed for binding to and neutralization by mab 3H5. We constructed 13 such DEN2 mutants that contained a single amino acid substitution in the region between positions 383 and 393 of DEN2 E. Each single substitution in the region spanning positions 386 through 393 of DEN2 yielded a virus that was as reactive with mab 3H5 as the parental chimeric virus. These results are consistent with the extent of sequence conservation in the region. In contrast, 5 of 6 mutants that sustained an amino acid substitution at position 383, 384, or 385 failed to react with mab 3H5 as detected by immunofluorescence assay and failed to be neutralized by the mab. Interestingly, each of the 5 mab-resistant DEN2 mutants also exhibited reduced mouse neurovirulence compared to parental chimeric DEN2 when inoculated intracerebrally. These observations suggest that the Glu-Pro-Gly sequence at positions 383-386 of the DEN2 E is a component of the site against which mab 3H5 is directed. In the recently determined three-dimensional structure of the related tick-borne encephalitis virus E, the Glu-Pro-Gly sequence would be located on the lateral surface of the immunoglobulin-like domain that is proposed to bind to the host cell receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8874504     DOI: 10.1006/viro.1996.0550

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  44 in total

1.  Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells.

Authors:  W D Crill; J T Roehrig
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein.

Authors:  R J Hurrelbrink; P C McMinn
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  NMR solution structure and backbone dynamics of domain III of the E protein of tick-borne Langat flavivirus suggests a potential site for molecular recognition.

Authors:  Munia Mukherjee; Kaushik Dutta; Mark A White; David Cowburn; Robert O Fox
Journal:  Protein Sci       Date:  2006-06       Impact factor: 6.725

4.  Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein.

Authors:  Yorgo Modis; Steven Ogata; David Clements; Stephen C Harrison
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Computational analysis and identification of amino acid sites in dengue E proteins relevant to development of diagnostics and vaccines.

Authors:  Raja Mazumder; Zhang-Zhi Hu; C R Vinayaka; Jose-Luis Sagripanti; Simon D W Frost; Sergei L Kosakovsky Pond; Cathy H Wu
Journal:  Virus Genes       Date:  2007-05-17       Impact factor: 2.332

6.  Solution structure of the envelope protein domain III of dengue-4 virus.

Authors:  David E Volk; Yi-Chien Lee; Xin Li; Varatharasa Thiviyanathan; Gregory D Gromowski; Li Li; Ashley R Lamb; David W C Beasley; Alan D T Barrett; David G Gorenstein
Journal:  Virology       Date:  2007-03-29       Impact factor: 3.616

7.  Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes.

Authors:  Lidice Bernardo; Osmel Fleitas; Alequis Pavón; Lisset Hermida; Gerardo Guillén; Maria G Guzman
Journal:  Clin Vaccine Immunol       Date:  2009-09-02

8.  PrM- and cell-binding domains of the dengue virus E protein.

Authors:  S Wang; R He; R Anderson
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

Authors:  Gregory D Gromowski; Nicholas D Barrett; Alan D T Barrett
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.